Coronavirus company news summary - Rhinomed to trial nasal swab for children - Project N95 offers Quidel’s QuickVue At-Home OTC test - Verdict Medical Devices
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – Rhinomed to trial nasal swab for children – Project N95 offers Quidel’s QuickVue At-Home OTC test

08 Sep 2021

Abingdon Health has launched a score-card product, for use with its AbC-19 rapid test. The new product offers a semi-quantitative result suggesting the antibody response strength and potential immunity of the user. The AbC-19 lateral flow device identifies the presence of IgG neutralising antibodies to the SARS-CoV-2 spike protein. The accessory is intended to help gain better insights into immune response.

Rhinomed has received ethics approval to conduct a clinical trial of the world’s first nasal swab designed for children. Rhinoswab Junior is intended to obtain a nasal sample from children without the discomfort and distress linked to the combined throat and deep nasal (CTDN) swabs. The trial will be performed at The Royal Children’s Hospital Melbourne to compare Rhinoswab to the current standard of care CTDN swab in nearly 250 children for diagnosing respiratory viruses, including Covid-19.

Non-profit Project N95 has added Quidel’s QuickVue At-Home OTC COVID-19 Test to its product range. The rapid test can be used without prescription and delivers results in ten minutes. It is designed to qualitatively detect the nucleocapsid protein antigen from SARS-CoV-2 in people with or without symptoms. The test can be used with self-collected direct anterior nasal swab samples from people aged 14 years or above or with adult-collected anterior specimens from those aged two years or above.